University of Michigan spin-off NanoBio Corporation has received its second grant for vaccine development from the Bill and Melinda Gates Foundation. The new $6 million grant is for development of an intranasal vaccine for respiratory syncytial virus (RSV). No approved RSV vaccines are available currently. In 2005, prior to the spin off from UM, the company received $6.3 million from the Gates Foundation for intranasal vaccine development. Read the company’s press release.
Gates Foundation awards $6 million grant to NanoBio for intranasal RSV vaccine
published on
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
December 9-December 11: DDL 2026, Edinburgh, Scotland
April 27-30: RDD Europe 2027, Antibes, France
May 12-13: USP Joint Workshop: Quality and Product Performance Testing of Orally Inhaled and Nasal Drug Products, Rockville, MD, USA
June 30: RespireX 2027, Boston, MA, USA
